Independent Coverage Disclosure: First Look Equities has received no compensation from Cardiol Therapeutics for this coverage. It is independent visibility content — not investment advice or a recommendation. We offer paid IR-visibility services to public companies, including companies we cover. Full disclosure

Live Data & Filings — direct from the source

Quotes and filings for Cardiol Therapeutics open at their authoritative live sources. First Look Equities does not redistribute market data.

Health on the water · Company Research Profile

Cardiol Therapeutics (NASDAQ: CRDL).

First Look Equities has initiated corporate visibility coverage on Cardiol Therapeutics. We feature Cardiol as a clinical-stage biotechnology pioneer developing innovative, targeted anti-inflammatory therapies for cardiovascular disease. Their pipelines offer crucial cardioprotective clinical answers for high-performance leaders on land and at sea.

Share Platform:
Independent Coverage DisclosureFirst Look Equities has received no compensation from Cardiol Therapeutics for this coverage, which is independent visibility content produced at our own initiative. We do not provide investment advice, buy/sell recommendations, target prices, or valuations, and we are not a broker-dealer or registered investment adviser. We offer paid IR-visibility services to public companies, including companies we cover; if Cardiol Therapeutics engages us, this page will carry a Securities Act §17(b) compensation disclosure.

Key Identifiers

Ticker SymbolsNASDAQ: CRDL | TSX: CRDL
Lead CandidateCardiolRx™ (Oral Cannabidiol)
Focus AreaAnti-Inflammatory Heart Therapy
Primary TrialsPhase II Pericarditis & Myocarditis
Vessel EligibilityMiami Yacht Boardroom Eligible
CLINICAL DATA DASHBOARD

Progress in CardiolRx™ Clinical Trials.

Review Cardiol's current investigational treatments targeting inflammation in recurrent pericarditis and acute myocarditis.

Phase II MAVERIC-Pilot Results

Targeting debilitating pericardial inflammation.

Recurrent pericarditis is characterized by sharp chest pain and recurrent inflammation of the pericardial sac. It causes severe, life-altering morbidity.

Cardiol's MAVERIC-Pilot study reported positive top-line data in 2024, demonstrating significant, rapid reductions in pain (measured by Visual Analog Scale) and C-reactive protein (CRP), a key laboratory marker of systemic inflammation.

Phase II
Trial Status Completed
Significant
Pain & CRP Reduction

Clinical Takeaway

CardiolRx™ is designed to inhibit NLRP3 inflammasome activation, a key mediator in the development of cardiovascular inflammation. The positive trial results suggest CardiolRx™ represents a promising potential oral therapy for patients suffering from pericarditis pain.

Key Trial endpoints
  • Reduction of pain severity scores
  • Reduction of inflammation markers (CRP)
  • Assessment of safety & tolerability profile
Corporate Slides

Clinical Milestones & Narrative Deck.

Review highlights from Cardiol Therapeutics' corporate presentation. This deck outlines the clinical development of CardiolRx™ in acute myocarditis and recurrent pericarditis.

Click through slide-by-slide or view them in sequence to see the clinical trials and data supporting Cardiol's anti-inflammatory therapeutic pipeline.

Highlight Presentation Slides
Slide 1 of 14
ENGAGED DELIVERABLES

What an Initiated IR Package Looks Like.

Once a company engages First Look Equities to initiate visibility coverage, a structured set of deliverables goes live to establish a high-fidelity narrative footprint.

Upgrade to The Floating Roadshow

Companies under active coverage can upgrade their engagement at any time to include **The Uncharted Boardroom** Miami executive roadshow, hosting private target allocator presentations on the 102' Leopard yacht.

01. Research Initiation Page

A fully custom-scoped, optimized company coverage landing page (such as this) highlighting clinical trials, key catalysts, and corporate milestones in our Sovereign design system.

02. GEO & AI Search Audits

Systematic index optimization and structured dataset schemas to ensure LLM search engines (Perplexity, Gemini, ChatGPT) retrieve, summarize, and cite the company accurately.

03. Editorial Research Blog

Authoring of structured company features in our Insights hub (e.g., 'Health on the Water' profile) syndicated to target investor networks and active capital market channels.

04. Strategic Lead Funnel

Direct integration with our TimeBroker AI outreach tools to schedule 1-on-1 strategy calls with interested allocators, building a qualified meeting pipeline.

Executive Program Coordination

The Uncharted Boardroom: Connecting Executives on the Water.

First Look Equities coordinates exclusive private boardroom charters and strategic roadshow environments on our partner 102' Leopard yacht in Miami, Florida. We provide these facilities only for companies under active coverage.

Cardiol's executive team is eligible for the program, which organizes tarmac transit, white-glove Fontainebleau basecamp logistics, and presentation facilities to showcase clinical breakthroughs to qualified allocators.

102' Leopard Yacht boardroom environment in Miami
Hear the equity story — featured video
Company Highlights — sourced from the issuer's filings & releases

MAVERIC Phase III clinical trial enrollment exceeded 75% for the pivotal study of oral CardiolRx™ in recurrent pericarditis.

PR · May 2, 2026

Q1 2026 Form 6-K reports a cash position of $27.7M CAD supporting the clinical runway.

Form 6-K · May 15, 2026

Phase II MAVERIC-Pilot data showed rapid, clinically meaningful reduction in pericarditis pain and inflammation markers.

Company publications

Phase II ARCHER study is evaluating CardiolRx™ efficacy and safety in acute myocarditis.

Company pipeline
Continuing Disclosure & Material Events
May 14, 2026Filing

Form 6-K: Q1 2026 Financial Statements and MD&A

Quarterly report outlining cash runway ($27.7M CAD), MAVERIC Phase III enrollment exceeding 75%, and Board recruitment updates.

View source
May 1, 2026Press Release

Phase III MAVERIC Trial Recruitment Update

Recruitment exceeds 75% for the pivotal study evaluating the oral CardiolRx™ formulation in recurrent pericarditis.

View source

Timeline entries summarize Cardiol Therapeutics's own public filings and press releases and link to the underlying source. First Look Equities does not verify, rate, or opine on these disclosures.

This page is a live product demo

Want an investor page like Cardiol Therapeutics's — for your company?

First Look Equities × TimeBroker.ai build investor pages with an always-on SI investor desk (an automated assistant) that answers investor questions in real time — strictly from your public filings. Hosted here or built on your own site. A 30-second application starts your personalized demo.

Get Your IR Page

Interested in Initiating Coverage?

IR firms and public issuers can request coverage or coordinate private boardrooms. Book a 15-minute discovery call to align on goals.

Book a Strategy Call